ClinicalTrials.gg

Program

alirocumab

Also written as “Alirocumab”, “alirocumab SAR236553 (REGN727)” and “Alirocumab SAR236553 (REGN727)”.

Its studies are mostly in Hypercholesterolemia · Hyperlipoproteinemia Type II · Coronary Artery Disease · Homozygous Familial Hypercholesterolemia · Atherosclerosis, led by 3 companies.

Furthest: phase 4, since Dec 24, 201548 company-led studies, 1 open or runningNext primary completion: Dec 29, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi300 open or runningphase 4since Dec 24, 2015Feb 1, 2011none ahead
Regeneron Pharmaceuticals161 open or runningphase 4since Oct 28, 2016Nov 20, 2009Dec 29, 2026phase 2 · NCT07477704
Kobe University20 open or runningphase 4since May 7, 2018May 7, 2018none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 31 studies since Nov 20, 2009.

  1. Dec 22, 2014Phase 3 study in Heterozygous Familial HypercholesterolemiaRegeneron Pharmaceuticals · NCT02326220 · 62 enrolled · United States, Germany
  2. Jun 16, 2015Phase 3 study in HypercholesterolemiaSanofi · NCT02476006 · 998 enrolled · Austria, Belgium, Canada and more
  3. Oct 21, 20152 phase 3 studies in HypercholesterolemiaSanofi · NCT02584504, NCT02585778
  4. Dec 24, 2015Phase 4 study in DyslipidemiasSanofi · NCT02642159 · 413 enrolled · United States, Australia, Brazil and more
  5. Mar 16, 2016Phase 3 study in HypercholesterolemiaSanofi · NCT02715726 · 615 enrolled · China, India, Thailand
  6. Aug 31, 2016Phase 2 study in HypercholesterolemiaSanofi · NCT02890992 · 42 enrolled · United States, Canada, Czechia and more
  7. Oct 28, 2016Phase 4 study in HypercholesterolemiaRegeneron Pharmaceuticals · NCT02957682 · 2,176 enrolled · United States, Bulgaria, Chile and more
  8. Nov 29, 2016Phase 1 study in HypercholesterolemiaSanofi · NCT02979015 · 35 enrolled · China
  9. Dec 5, 2016Phase 4 study in HypercholesterolemiaSanofi · NCT02984982 · 206 enrolled · Japan
  10. May 15, 2017Phase 3 study in Homozygous Familial HypercholesterolemiaRegeneron Pharmaceuticals · NCT03156621 · 69 enrolled · United States, Austria, Canada and more
  11. Apr 18, 20182 phase 3 studies in HypercholesterolemiaSanofi · NCT03510884, NCT03510715
  12. May 7, 2018Kobe University's first studies: 2 phase 4 studies in Coronary Artery DiseaseNew to Kobe UniversityKobe University · NCT03552432, NCT03529253
  13. Sep 6, 2018Phase 4 study in Heterozygous Familial HypercholesterolemiaRegeneron Pharmaceuticals · NCT03694197 · 1,389 enrolled · United States, Bulgaria, Estonia and more
  14. Mar 12, 2026Phase 2 study in HypercholesterolemiaRegeneron Pharmaceuticals · NCT07477704 · 438 enrolled · United States

Ahead

  1. Dec 29, 2026Primary completion: phase 2 study in HypercholesterolemiaRegeneron Pharmaceuticals · NCT07477704

TargetBeta

PCSK9 →read by rule
“A human immunoglobulin G1 (IgG1) monoclonal antibody directed against human proprotein convertase subtilisin/kexin type 9 (PCSK9), that can be used in the treatment of hypercholesterolemia”NCIt, by rule
“Subtilisin/kexin type 9 inhibitor”ChEMBL 37, by rule

Other programs on PCSK9

ProgramCompanyFurthest phaseStudies
evolocumabruleAmgenphase 445
inclisiranruleNovartisphase 437
lerodalcibeprulelib-therapeutics-llcphase 314
tafolecimabruleInnovent Biologicsphase 38
recaticimabruleJiangsu HengRui Medicinephase 37
QLC7401ruleQilu Pharmaceuticalphase 35
SAL003ruleShenzhen Salubris Pharmaceuticalsphase 33
VERVE-102Eli Lillyphase 22
DNV001rulehangzhou-dinovate-biotech-co-ltdphase 21
RBD7022ruleQilu Pharmaceuticalphase 12

Studies

All 48 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07477704Hypercholesterolemia · United States2Active, not recruitingRegeneron PharmaceuticalsDec 29, 2026438
NCT03694197Heterozygous Familial Hypercholesterolemia · United States, Bulgaria, Estonia and more4TerminatedRegeneron PharmaceuticalsApr 8, 20201,389
NCT03552432Coronary Artery Disease · Japan4UNKNOWNKobe UniversitySep 30, 202024
NCT03529253Coronary Artery Disease · Japan4UNKNOWNKobe UniversitySep 30, 202030
NCT03510884Hypercholesterolemia · United States, Argentina, Austria and more3CompletedSanofiJan 14, 2021153
NCT03510715Hypercholesterolemia · Brazil, Canada, Denmark and more3CompletedSanofiFeb 17, 202018
NCT03156621Homozygous Familial Hypercholesterolemia · United States, Austria, Canada and more3CompletedRegeneron PharmaceuticalsSep 27, 201969
NCT02984982Hypercholesterolemia · Japan4CompletedSanofiJul 27, 2018206
NCT02979015Hypercholesterolemia · China1CompletedSanofiNov 27, 201735
NCT02957682Hypercholesterolemia · United States, Bulgaria, Chile and more4CompletedRegeneron PharmaceuticalsMar 5, 20202,176
NCT02890992Hypercholesterolemia · United States, Canada, Czechia and more2CompletedSanofiSep 13, 201842
NCT02715726Hypercholesterolemia · China, India, Thailand3CompletedSanofiAug 6, 2018615
NCT02642159Dyslipidemias · United States, Australia, Brazil and more4CompletedSanofiMar 22, 2017413
NCT02585778Hypercholesterolemia · United States, Austria, Belgium and more3CompletedSanofiApr 3, 2017517
NCT02584504Hypercholesterolemia · Japan3CompletedSanofiApr 5, 2017163
NCT02476006Hypercholesterolemia · Austria, Belgium, Canada and more3CompletedSanofiApr 12, 2019998
NCT02326220Heterozygous Familial Hypercholesterolemia · United States, Germany3CompletedRegeneron PharmaceuticalsJan 31, 201662
NCT02107898Hypercholesterolemia · Japan3CompletedSanofiJan 2015216
NCT02023879Hypercholesterolemia · United States, Australia, Belgium and more3CompletedSanofiOct 27, 2014233
NCT01959971Hypercholesterolemia · United States1CompletedSanofiMay 201520
NCT01954394Hypercholesterolemia · United States, Argentina, Austria and more3CompletedSanofiJun 30, 2017986
NCT01926782Hypercholesterolemia · United States, Bulgaria, Canada and more3CompletedRegeneron PharmaceuticalsSep 2014803
NCT01812707Hypercholesterolemia · Japan2CompletedSanofiJan 2014100
NCT01785329Hypercholesterolemia · United Kingdom1CompletedSanofiJul 201360
NCT01730053Hypercholesterolemia · United States, Australia, Canada and more3CompletedRegeneron PharmaceuticalsApr 30, 2014305
NCT01730040Hypercholesterolemia · United States, Australia, Canada and more3CompletedRegeneron PharmaceuticalsApr 2014355
NCT01709513Hypercholesterolemia · United States, Austria, Canada and more3CompletedRegeneron PharmaceuticalsMay 31, 2014314
NCT01709500Heterozygous Familial Hypercholesterolemia · Czech Republic, Netherlands, Norway and more3CompletedRegeneron PharmaceuticalsMay 2014249
NCT01670734Hypercholesterolemia · France, Moldova, Republic of1CompletedSanofiMay 201325
NCT01663402Atherosclerosis · United States, Argentina, Australia and more3CompletedSanofiJan 23, 201818,924
NCT01644474Hypercholesterolemia · United States, Belgium, Finland and more3CompletedSanofiJul 2013103
NCT01644188Hypercholesterolemia · United States, Canada, Denmark and more3CompletedSanofiMay 2014720
NCT01644175Hypercholesterolemia · United States3CompletedSanofiApr 2014316
NCT01623115Hypercholesterolemia · United States, Austria, Canada and more3CompletedSanofiApr 2014486
NCT01617655Hypercholesterolemia · United States, Canada, Netherlands and more3CompletedSanofiMay 2014107
NCT01604824Hypercholesterolemia · United States, France2CompletedRegeneron PharmaceuticalsJun 2, 201423
NCT01576484Hypercholesterolemia · United States, Canada2CompletedRegeneron PharmaceuticalsDec 22, 201658
NCT01507831Hypercholesterolemia · United States, Argentina, Belgium and more3CompletedSanofiNov 20142,341
NCT01448304Hypercholesterolemia · United States1CompletedSanofiSep 201124
NCT01448239Hypercholesterolemia · United States1CompletedSanofiMay 201124
NCT01448317Hypercholesterolemia · Japan1CompletedSanofiJan 201232
NCT01443650Hypercholesterolemia · United States1CompletedSanofiNov 201136
NCT01288469Hypercholesterolemia · United States2CompletedSanofiSep 201192
NCT01288443Hypercholesterolemia · United States2CompletedSanofiDec 2011183
NCT01266876Hypercholesterolemia · United States, Canada2CompletedRegeneron PharmaceuticalsNov 201177
NCT01161082Hypercholesterolemia · United States1CompletedRegeneron PharmaceuticalsMay 201172
NCT01074372Healthy Volunteers · United States1CompletedRegeneron PharmaceuticalsNov 201032
NCT01026597Healthy · United States1CompletedRegeneron PharmaceuticalsOct 201040

How it is read

Names in the registry

  • “Alirocumab”, 28 entries
  • “alirocumab SAR236553 (REGN727)”, 8 entries
  • “Alirocumab SAR236553 (REGN727)”, 2 entries
  • “alirocumab”, 2 entries
  • “REGN727”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.